Drugs / SCH708980
re-read 2 minutes ago

SCH708980

Monoclonal antibody targets IL10 via inhibition

Developed for
visceral leishmaniasis
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01437020 immunotherapy induced hypophysitis, visceral leishmaniasis National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SCH708980 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437020
Action Inhibit “anti-IL-10 monoclonal antibody” NCT01437020
Modality Monoclonal antibody “Anti-IL-10 Monoclonal AntibodyNCT01437020
Route Intravenous “a single intravenous (IV) infusion of SCH708980” NCT01437020
Target IL10 “anti-IL-10 monoclonal antibody” NCT01437020